Mifepristone: Phase I started

Corcept began an open-label, U.S. Phase I trial to evaluate once-daily oral mifepristone plus IV Halaven eribulin. The first, dose-escalating portion of the trial will enroll up to 20 patients with metastatic breast cancer and the second portion will enroll up to an additional 20 patients with glucocorticoid receptor-positive metastatic triple-negative breast cancer (TNBC). ...